SCHEMBL6555263

SCHEMBL6555263

NC(=O)c1ncn([C@@H]2O[C@H](CP(=O)(O)O)[C@@H](O)[C@H]2O)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
ADORA1 P30542 2/20 0.73
ALDH1A1 P00352 2/20 0.73
TSHR P16473 2/20 0.73
GLA P06280 1/20 0.73
EIF4E P06730 1/20 0.73
CYP3A4 P08684 1/20 0.73
TOP1 P11387 1/20 0.73
THPO P40225 1/20 0.73
PMP22 Q01453 1/20 0.73
PNP P00491 3/20 0.56
ATIC P31939 2/20 0.43
FBP1 P09467 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
KDM4E B2RXH2 2/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12300345 0.89 LMNA (0.72) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL24024426 0.88 LMNA (0.70) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL24024696 0.88 LMNA (0.70) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL1200226 0.88 LMNA (0.90) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL572829 0.88 LMNA (0.90) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL5473652 0.87 LMNA (0.88) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL6913951 0.85 LMNA (0.66) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin Monophosphate SCHEMBL12727825 0.85 LMNA (0.69) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin Monophosphate SCHEMBL1508870 0.85 LMNA (0.69) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin Monophosphate SCHEMBL10882076 0.85 LMNA (0.69) LMNASMN1; SMN2ADORA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485396-A2 NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS Biota, Inc. (US) 2004-12-15 EP disclosed
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 US disclosed
WO-2003073989-A2 NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS BIOTA, INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885SMN1; SMN2 2624/4885ADORA1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.